Reduced Expression of the NMDA Receptor-Interacting Protein SynGAP Causes Behavioral Abnormalities that Model Symptoms of Schizophrenia

被引:79
|
作者
Guo, Xiaochuan [1 ,2 ]
Hamilton, Peter J. [3 ]
Reish, Nicholas J. [1 ,2 ,4 ]
Sweatt, J. David [1 ,2 ]
Miller, Courtney A. [1 ,2 ]
Rumbaugh, Gavin [1 ,2 ,3 ]
机构
[1] Univ Alabama, Dept Neurobiol, Birmingham, AL 35294 USA
[2] Univ Alabama, Evelyn F McKnight Brain Inst, Birmingham, AL 35294 USA
[3] UAB, Summer Program Neurosci SPIN, Birmingham, AL USA
[4] UAB, Med Scientist Training Program MSTP, Birmingham, AL USA
关键词
schizophrenia; NMDA receptor; postsynaptic density; plasticity; hyperactivity; fear conditioning; GTPASE-ACTIVATING PROTEIN; LONG-TERM POTENTIATION; SYNAPTIC PLASTICITY; GLUTAMATE-RECEPTOR; AMPA RECEPTORS; POSTSYNAPTIC DENSITY-95; KINASE-II; MICE; TRAFFICKING; RAS;
D O I
10.1038/npp.2008.223
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Abnormal function of NMDA receptors is believed to be a contributing factor to the pathophysiology of schizophrenia. NMDAR subunits and postsynaptic-interacting proteins of these channels are abnormally expressed in some patients with this illness. In mice, reduced NMDAR expression leads to behaviors analogous to symptoms of schizophrenia, but reports of animals with mutations in core postsynaptic density proteins having similar a phenotype have yet to be reported. Here we show that reduced expression of the neuronal RasGAP and NMDAR-associated protein, SynGAP, results in abnormal behaviors strikingly similar to that reported in mice with reduced NMDAR function. SynGAP mutant mice exhibited nonhabituating and persistent hyperactivity that was ameliorated by the antipsychotic clozapine. An NMDAR antagonist, MK-801, induced hyperactivity in normal mice but SynGAP mutants were less responsive, suggesting that NMDAR hypofunction contributes to this behavioral abnormality. SynGAP mutants exhibited enhanced startle reactivity and impaired sensory-motor gating. These mice also displayed a complete lack of social memory and a propensity toward social isolation. Finally, SynGAP mutants had deficits in cued fear conditioning and working memory, indicating abnormal function of circuits that control emotion and choice. Our results demonstrate that SynGAP mutant mice have gross neurological deficits similar to other mouse models of schizophrenia. Because SynGAP interacts with NMDARs, and the signaling activity of this protein is regulated by these channels, our data in dicate that SynGAP lies downstream of NMDARs and is a required intermediate for normal neural circuit function and behavior. Taken together, these data support the idea that schizophrenia may arise from abnormal signaling pathways that are mediated by NMDA receptors. Neuropsychopharmacology (2009) 34, 1659-1672; doi:10.1038/npp.2008.223; published online 14 January 2009
引用
收藏
页码:1659 / 1672
页数:14
相关论文
共 50 条
  • [21] Neto1 Is a Novel CUB-Domain NMDA Receptor-Interacting Protein Required for Synaptic Plasticity and Learning
    Ng, David
    Pitcher, Graham M.
    Szilard, Rachel K.
    Sertie, Andrea
    Kanisek, Marijana
    Clapcote, Steven J.
    Lipina, Tatiana
    Kalia, Lorraine V.
    Joo, Daisy
    McKerlie, Colin
    Cortez, Miguel
    Roder, John C.
    Salter, Michael W.
    McInnes, Roderick R.
    PLOS BIOLOGY, 2009, 7 (02): : 278 - 300
  • [22] Schizophrenia-Like Dopamine Release Abnormalities in a Mouse Model of NMDA Receptor Hypofunction
    Nakao, Kazuhito
    Jeevakumar, Vivek
    Jiang, Sunny Zhihong
    Fujita, Yuko
    Diaz, Noelia B.
    Annan, Carlos A. Pretell
    Jaunarajs, Karen L. Eskow
    Hashimoto, Kenji
    Belforte, Juan E.
    Nakazawa, Kazu
    SCHIZOPHRENIA BULLETIN, 2019, 45 (01) : 138 - 147
  • [23] Co-expression of activin receptor-interacting protein 1 and 2 in mouse nerve cells
    Qi, Yan
    Ge, Jing-Yan
    Wang, Yi-Nan
    Liu, Hai-Yan
    Li, Yun-Man
    Liu, Zhong-Hui
    Cui, Xue-Ling
    NEUROSCIENCE LETTERS, 2013, 542 : 53 - 58
  • [24] Null mutation of peroxisome proliferator-activated receptor-interacting protein in mammary glands causes defective mammopoiesis
    Qi, C
    Kashireddy, P
    Zhu, YWT
    Rao, SM
    Zhu, YJ
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (32) : 33696 - 33701
  • [25] Expression Profile and Tissue-Specific Distribution of the Receptor-Interacting Protein 3 in BALB/c Mice
    Qingnan Wang
    Meng Yu
    Kaizhao Zhang
    Jianxin Liu
    Pan Tao
    Shikun Ge
    Zhangyong Ning
    Biochemical Genetics, 2016, 54 : 360 - 367
  • [26] Receptor-Interacting Protein Kinase-3 Expression Impacts Ocular Vascular Development and Pathological Neovascularization
    Song, Yong-Seok
    Wang, Shoujian
    Park, Sunyoung
    Hanna, Barbara
    Johnson, Kelsey J.
    Darjatmoko, Soesiawati R.
    Saghiri, Mohammad Ali
    Saghiri, Ali Mohammad
    Liu, Bo
    Sorenson, Christine M.
    Sheibani, Nader
    CELLS, 2024, 13 (24)
  • [27] Elevated expression of thyroid hormone receptor-interacting protein 13 drives tumorigenesis and affects clinical outcome
    Wang Dazhi
    Zhang Mengxi
    Chen Fufeng
    Yan Meixing
    BIOMARKERS IN MEDICINE, 2017, 11 (01) : 19 - 31
  • [28] Expression Profile and Tissue-Specific Distribution of the Receptor-Interacting Protein 3 in BALB/c Mice
    Wang, Qingnan
    Yu, Meng
    Zhang, Kaizhao
    Liu, Jianxin
    Tao, Pan
    Ge, Shikun
    Ning, Zhangyong
    BIOCHEMICAL GENETICS, 2016, 54 (04) : 360 - 367
  • [29] Expression of receptor interacting protein 1 and receptor interacting protein 3 oval cells in a rat model of hepatocarcinogenesis
    Wojcik, Marta
    Bobowiec, Ryszard
    Lisiecka, Urszula
    Smiech, Anna
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2018, 15 (05) : 4448 - 4456
  • [30] GABAA and NMDA receptor density alterations and their behavioral correlates in the gestational methylazoxymethanol acetate model for schizophrenia
    Kiemes, Amanda
    Gomes, Felipe, V
    Cash, Diana
    Uliana, Daniela L.
    Simmons, Camilla
    Singh, Nisha
    Vernon, Anthony C.
    Turkheimer, Federico
    Davies, Cathy
    Stone, James M.
    Grace, Anthony A.
    Modinos, Gemma
    NEUROPSYCHOPHARMACOLOGY, 2022, 47 (03) : 687 - 695